

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT**  
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.  
RLL-317US

In Re Application of: **SHARMA et al.**

Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/539,130		Unknown	26815	Unknown	2716

Title: **PURE LEVOFLOXACIN HEMIHYDRATE AND PROCESSES FOR PREPARATION THEREOF**

**Payment of Fee**

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))


- ☐ A check in the amount of \_\_\_\_\_ is attached.
- ☒ The Director is hereby authorized to charge and credit Deposit Account No. 50-0912  
as described below.
- ☐ Charge the amount of \_\_\_\_\_
- ☐ Credit any overpayment.
- ☒ Charge any additional fee required.
- ☐ Payment by credit card. Form PTO-2038 is attached.

**WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.**

**Certificate of Transmission by Facsimile\***

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fa
_____ (Date)
_____ Signature
_____ Typed or Printed Name of Person Signing Certificate

**Certificate of Mailing by <sup>Express</sup> First Class Mail**

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as <sup>Express</sup> <del>first class</del> mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 4.9(a)] on June 19, 2006 <sup>1.10</sup>
_____ (Date)
 Signature of Person Mailing Correspondence
Christine Kenedy Typed or Printed Name of Person Mailing Certificate

\*This certificate may only be used if paying by deposit account.

  
Signature

Dated: June 19, 2006

William D. Hare, Esq.  
Reg. No. 44,739

CUSTOMER NO. 26815

CC:

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT**  
**(Under 37 CFR 1.97(b) or 1.97(c))**

Docket No.  
**RLL-317US**

In Re Application Of: **SHARMA et al.**

Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/539,130		Unknown	26815	Unknown	2716

Title: **PURE LEVOFLOXACIN HEMIHYDRATE AND PROCESSES FOR PREPARATION THEREOF**

Address to:  
**Commissioner for Patents**  
**P.O. Box 1450**  
**Alexandria, VA 22313-1450**

**37 CFR 1.97(b)**

1. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

**37 CFR 1.97(c)**

2. ☐ The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:

☐ the statement specified in 37 CFR 1.97(e);

**OR**

☐ the fee set forth in 37 CFR 1.17(p).

**INFORMATION DISCLOSURE CITATION**

Docket No.: RLL-317US

Serial No.: 10/539,130

Applicants: SHARMA *et al.*

Filed: 6/15/2005

Group:

**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A1	5,053,407	10/1/1991	Hayakawa <i>et al.</i>	514	230.2	
	A2	5,545,737	8/13/1996	Sato <i>et al.</i>	544	101	

**FOREIGN PATENT DOCUMENTS**

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES   NO	
	B1	EP 0 444 678	9/4/1991	EPO	C07D	498/06		
	B2	WO 03/045329	6/5/2003	PCT	A61K			

**OTHER DOCUMENTS** (Including Author, Title, Date, Pertinent Pages, Etc.)

	C1	Kitaoka et al, "Effect of Dehydration on the Formation of Levofloxacin Pseudopolymorphs", <i>Chemical &amp; Pharmaceutical Bulletin</i> , <u>43</u> (4):649-653 (1995)
	C2	Araki et al, "Chemical structure and physicochemical properties of (S)-(-)-9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido-[1,2,3-de] [1,4]benzoxazine-6-carboxylic acid hemihydrate (DR-3355)", <i>Iyakuhi Kenkyu</i> , <u>22</u> (3):424-434 (1991)

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.